KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2016 - 2025)

Biomarin Pharmaceutical's Change in Accured Expenses history spans 17 years, with the latest figure at -$53.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses changed 0.16% year-over-year to -$53.3 million, compared with a TTM value of $66.1 million through Dec 2025, up 348.05%, and an annual FY2025 reading of $66.1 million, up 348.05% over the prior year.
  • Change in Accured Expenses for Q4 2025 was -$53.3 million at Biomarin Pharmaceutical, down from $113.9 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $122.3 million in Q3 2024, with the low at -$78.1 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is $9.0 million, with a median of $3.2 million recorded in 2022.
  • Year-over-year, Change in Accured Expenses surged 23230.7% in 2022 and then tumbled 1952.98% in 2023.
  • Tracing BMRN's Change in Accured Expenses over 5 years: stood at $15.4 million in 2021, then soared by 303.83% to $62.3 million in 2022, then plummeted by 152.59% to -$32.7 million in 2023, then tumbled by 62.63% to -$53.3 million in 2024, then decreased by 0.16% to -$53.3 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Change in Accured Expenses are -$53.3 million (Q4 2025), $113.9 million (Q3 2025), and $8.2 million (Q2 2025).